Bausch Health Companies (BHC) Research & Development (2009 - 2026)

Bausch Health Companies has disclosed Research & Development across 18 years of filings, most recently posting $163.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $163.0 million, up 13.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $564.0 million (down 7.24% YoY), and the FY2025 annual result was $629.0 million, up 2.11% from the prior year.
• Research & Development came in at $163.0 million for Q1 2026 at Bausch Health Companies, up from $161.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $163.0 million in Q4 2024 to a low of $81.0 million in Q3 2025.
• The 5-year median for Research & Development is $151.0 million (2024), against an average of $144.5 million.
• Across the five-year window, Research & Development rose 22.83% in 2023 and tumbled 44.52% in 2025, its largest moves.
• Bausch Health Companies' Research & Development stood at $142.0 million in 2022, then gained by 7.04% to $152.0 million in 2023, then climbed by 7.24% to $163.0 million in 2024, then declined by 1.23% to $161.0 million in 2025, then climbed by 1.24% to $163.0 million in 2026.
• The last three Research & Development figures came in at $163.0 million (Q1 2026), $161.0 million (Q4 2025), and $81.0 million (Q3 2025), per Business Quant data.